FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Consensus Needs to Come Down on Intercept (ICPT) after FDA Review is Extended - Leerink
December 18, 2015 8:44 AM ESTLeerink Partners analyst, Joseph Schwartz noted that Intercept Pharmaceuticals (NASDAQ: ICPT) announced that the FDA has extended the PDUFA date for its priority review application of Obeticholic acid (OCA) in primary biliary cirrhosis/ cholangitis (PBC) by 3 mos. to May 29, 2016. ICPT stated that FDA had requested additional information, to which ICPT has... More
FDA Pushed Back Intercept Pharma's (ICPT) PDUFA Date; Seeks More Data - Baird Maintains Outperform
December 18, 2015 7:41 AM ESTBaird maintained an Outperform rating and $346.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following the company's announcement that the FDA pushed out its Prescription Drug User Fee Act (PDUFA) date for the priority review of obeticholic acid (OCA) in primary biliary cholangitis (PBC). The... More
